Global Prolastin Market Size By Type (20ml, 40ml), By Application (Hospital, Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Prolastin Market was valued at USD 1.3 billion in 2023 and is projected to reach USD 2.5 billion by 2031, expanding at a CAGR of 8.6% during the forecast period from 2023 to 2031. Prolastin, a plasma-derived alpha-1 antitrypsin (AAT) augmentation therapy, is primarily used for the treatment of Alpha-1 Antitrypsin Deficiency (AATD)—a rare genetic condition that can lead to severe lung and liver diseases. The rising incidence of AATD, growing awareness, advancements in plasma fractionation technologies, and increasing investments in rare disease therapeutics are key contributors to market growth.

Drivers:

1. Growing Prevalence of Alpha-1 Antitrypsin Deficiency:

Increased diagnosis of AATD across North America and Europe, along with better screening tools and clinical education, is driving demand for Prolastin therapies.

2. Advancements in Plasma Collection and Fractionation:

Technological innovations in plasma collection and fractionation processes have improved the quality, safety, and supply of AAT therapies, enhancing Prolastin production capabilities.

3. Rising Investments in Rare Disease Research:

Governments and private players are increasingly funding orphan drug development, encouraging pharmaceutical innovation and boosting the growth trajectory for Prolastin.

Restraints:

1. High Cost of Therapy:

Prolastin treatment is expensive, often costing tens of thousands of dollars annually. Limited reimbursement policies and affordability concerns in developing regions may restrict market penetration.

2. Limited Awareness in Developing Regions:

Lack of awareness about AATD and the availability of treatment options like Prolastin in low- and middle-income countries can hinder global market growth.

Opportunity:

1. Expansion into Emerging Markets:

As healthcare infrastructure improves in Asia-Pacific and Latin America, opportunities arise for companies to expand their footprint by offering educational campaigns, early diagnostics, and affordable pricing strategies.

2. Innovations in Drug Delivery:

Development of subcutaneous formulations and home infusion services for Prolastin may improve patient compliance and expand its adoption across broader demographics.

Market by System Type Insights:

The Intravenous Prolastin segment dominated the market in 2023. Despite its clinical effectiveness, researchers and companies are exploring more patient-friendly delivery systems. Upcoming innovations in subcutaneous delivery could gain traction during the forecast period, offering ease-of-use and reducing dependency on clinic-based infusions.

Market by End-use Insights:

The Hospital & Specialty Clinics segment held the largest market share in 2023, driven by the need for accurate diagnosis and infusion-based therapy. However, Homecare Settings are expected to grow rapidly, supported by rising patient preference for at-home treatments and the development of portable drug delivery devices.

Market by Regional Insights:

North America led the global Prolastin market in 2023 due to higher diagnosis rates, availability of specialized treatment centers, and favorable reimbursement policies. Europe followed closely, benefiting from well-established rare disease frameworks. Asia-Pacific is projected to witness the fastest growth owing to increasing awareness, improving healthcare access, and growing investments in rare disease treatment infrastructure.

Competitive Scenario:

Key players in the global Prolastin market include Grifols S.A., CSL Behring, Takeda Pharmaceutical Company Limited, Kamada Ltd., and Shire (now part of Takeda). These companies are focusing on R&D investments, strategic collaborations, and expanding plasma collection networks. For example:

In 2023, Grifols expanded its plasma donation centers across the U.S. to meet increasing demand for AAT therapies.

In 2022, CSL Behring announced positive clinical trial results for its next-generation subcutaneous AAT therapy.

In 2021, Kamada Ltd. entered into a partnership to commercialize Prolastin-C in emerging European markets.

Scope of Work – Global Prolastin Market

Report Metric Details

Market Size (2023) USD 1.3 billion

Projected Market Size (2031) USD 2.5 billion

CAGR (2023–2031) 8.6%

Market Segments System Type (Intravenous, Subcutaneous), End-use (Hospitals & Clinics, Homecare)

Growth Drivers Rising AATD prevalence, plasma tech advancements, rare disease funding

Opportunities Expansion in emerging markets, innovations in drug delivery

Key Market Developments:

2023: Grifols opens 10 new plasma centers across North America to expand production capacity for Prolastin.

2022: CSL Behring’s novel subcutaneous AAT therapy shows promise in Phase III trials, improving patient convenience.

2021: Takeda launched awareness campaigns in Asia to educate physicians on AATD diagnosis and Prolastin usage.

FAQs:

1) What is the current market size of the Global Prolastin Market?

The market was valued at USD 1.3 billion in 2023.

2) What is the major growth driver of the Global Prolastin Market?

The primary driver is the growing prevalence and diagnosis of Alpha-1 Antitrypsin Deficiency (AATD).

3) Which is the largest region during the forecast period in the Global Prolastin Market?

North America is expected to dominate the market during the forecast period.

4) Which segment accounted for the largest market share in Global Prolastin Market?

The Intravenous Prolastin segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Prolastin Market?

Grifols S.A., CSL Behring, Takeda, Kamada Ltd., and Shire (Takeda).

Let me know if you'd like a visual chart or downloadable format for this report.